INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Medical University of Lodz
Łódź, PoloniaPublicaciones en colaboración con investigadores/as de Medical University of Lodz (8)
2022
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood, Vol. 140, Núm. 11, pp. 1200-1228
2020
-
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509
2016
-
A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis
Oncotarget, Vol. 7, Núm. 37, pp. 59029-59048
2015
-
Type 2 diabetes-related variantsinfluence the risk of developing multiple myeloma: Results from the IMMEnSE consortium
Endocrine-Related Cancer, Vol. 22, Núm. 4, pp. 545-559
2014
-
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477
-
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
Blood, Vol. 123, Núm. 26, pp. 4136-4142
2011
-
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial
British Journal of Haematology, Vol. 153, Núm. 2, pp. 212-221